Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.

Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA.

Nature. 2005 Mar 31;434(7033):644-8. Erratum in: Nature. 2007 Mar 1;446(7131):102.

2.

ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.

Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ.

Nature. 2005 Mar 31;434(7033):648-52.

3.

ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis.

Verma P, Dalal K.

J Cell Biochem. 2011 Dec;112(12):3507-14. doi: 10.1002/jcb.23298. Review.

PMID:
21815191
4.

Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models.

Li J, Anemaet W, Diaz MA, Buchanan S, Tortorella M, Malfait AM, Mikecz K, Sandy JD, Plaas A.

J Orthop Res. 2011 Apr;29(4):516-22. doi: 10.1002/jor.21215. Epub 2010 Oct 26.

5.

Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis.

Chia SL, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J, Vincent T.

Arthritis Rheum. 2009 Jul;60(7):2019-27. doi: 10.1002/art.24654.

6.

An aggrecanase and osteoarthritis.

Karsenty G.

N Engl J Med. 2005 Aug 4;353(5):522-3. No abstract available.

PMID:
16079379
7.

Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.

Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD.

J Biol Chem. 2002 Jun 21;277(25):22201-8. Epub 2002 Apr 15.

8.

ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage.

Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, Arai M, DiBlasio-Smith E, Dorner AJ, Georgiadis KE, Jin M, Tan XY, Morris EA, LaVallie ER.

Matrix Biol. 2004 Jul;23(4):219-30.

PMID:
15296936
9.

ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo.

Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, Bateman JF, Pritchard MA, Fosang AJ.

Arthritis Rheum. 2005 May;52(5):1461-72.

10.

The cleavage of biglycan by aggrecanases.

Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ.

Osteoarthritis Cartilage. 2006 Nov;14(11):1147-54. Epub 2006 Jun 30.

11.

Protective effect of lentivirus-mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis.

Chu X, You H, Yuan X, Zhao W, Li W, Guo X.

Int J Mol Med. 2013 May;31(5):1222-8. doi: 10.3892/ijmm.2013.1318. Epub 2013 Mar 26.

PMID:
23546441
12.

Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis.

Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, Lee YJ, Song YW, Herzog C, Theilmeier G, Pap T.

Nat Med. 2009 Sep;15(9):1072-6. doi: 10.1038/nm.1998. Epub 2009 Aug 16.

PMID:
19684582
13.

Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.

Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B.

Biochem J. 1999 Nov 15;344 Pt 1:61-8.

14.

Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice.

Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, Flannery CR, Kanki K, Wang E, Peluso D, Yang Z, Majumdar MK, Morris EA.

Arthritis Rheum. 2004 Aug;50(8):2547-58.

15.

Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5.

Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW.

Arthritis Rheum. 2007 Feb;56(2):575-85.

16.

Thyroid hormone enhances aggrecanase-2/ADAM-TS5 expression and proteoglycan degradation in growth plate cartilage.

Makihira S, Yan W, Murakami H, Furukawa M, Kawai T, Nikawa H, Yoshida E, Hamada T, Okada Y, Kato Y.

Endocrinology. 2003 Jun;144(6):2480-8.

PMID:
12746310
17.

Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS.

J Clin Invest. 1997 Jul 1;100(1):93-106.

18.

Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis.

Apte SS.

Biochem J. 2016 Jan 1;473(1):e1-4. doi: 10.1042/BJ20151072. Review.

PMID:
26657033
19.

LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage.

Yamamoto K, Troeberg L, Scilabra SD, Pelosi M, Murphy CL, Strickland DK, Nagase H.

FASEB J. 2013 Feb;27(2):511-21. doi: 10.1096/fj.12-216671. Epub 2012 Oct 11.

20.

Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis.

Singer II, Scott S, Kawka DW, Bayne EK, Weidner JR, Williams HR, Mumford RA, Lark MW, McDonnell J, Christen AJ, Moore VL, Mudgett JS, Visco DM.

Osteoarthritis Cartilage. 1997 Nov;5(6):407-18.

PMID:
9536289

Supplemental Content

Support Center